CluePoints Appoints Usama Dar as Chief Product and Technology Officer
Usama has worked in leadership roles across some exciting organizations, including Westwing, Sciensus, Elsevier, The Guardian and Huawei. With a career spanning eCommerce, SaaS, and AI, he loves building and leading teams to create impactful products.
To learn more about CluePoints' award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R3), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
View original content:https://www.prnewswire.com/news-releases/cluepoints-appoints-usama-dar-as-chief-product-and-technology-officer-302416983.html
SOURCE CluePoints
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pixelgen Technologies Closes $15.5M Oversubscribed Series B to Accelerate Global Expansion
- ICG: Oxy Capital Comments on the Half-Year Results of Irish Continental Group PLC (“ICG”) and the Independent Board’s Response to Its Letter
- FDA accepts Teva's drug application for Tourette syndrome therapy in children
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share